Back to Orexin b research
orexin b other n=15 2014-09 ClinicalTrials

Novel Foods' Satiety Effects on Gut-Brain Axis Explored in Human Study

Metabolic Effect of New Foods Through Gut-brain Axis

Background

Obesity and overweight are pressing global health concerns, often influenced by dietary factors and the body's satiety signals. Understanding how specific food components affect feelings of fullness (satiety) is vital for developing effective weight management strategies. This study aimed to investigate the satiating efficiency of novel food ingredients, specifically melanoidins and bitter compounds, by evaluating their impact on the human gut-brain axis.

Results

This record describes the design of a completed study, but specific quantitative results regarding the satiating efficiency of melanoidins and bitter compounds are not detailed here. The study was designed to measure human gut-brain responses, including metabolic changes, after ingesting novel foods. Researchers aimed to determine how these specific food components influence feelings of fullness over a 3-hour post-meal period, with blood samples collected at five distinct time points. > The primary objective was to evaluate if novel foods containing melanoidins and bitter compounds could significantly alter satiety signals and gut-brain axis activity in humans. While the data is not presented in this registration, the study's completion in 2015 suggests that these measurements were taken from 15 participants across two distinct food interventions.

Why It Matters

Understanding how specific food components like melanoidins and bitter compounds affect satiety could lead to the development of new functional foods. These foods could potentially help individuals manage obesity and overweight by promoting longer-lasting feelings of fullness and reducing overall caloric intake. If these compounds prove effective, they could be incorporated into everyday diets to improve public health and weight management strategies. Future steps would involve the publication of the study's findings, which could then inform larger-scale human trials or product development.


orexin b protocol relevant
Source: clinicaltrials:NCT01851304 · Ingested 2026-04-24 · Digest: gemini-2.5-flash